Tourmaline Bio, Inc.
TRML
$15.10
-$0.64-4.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -82.87M | -73.21M | -63.88M | -49.29M | -47.93M |
| Total Depreciation and Amortization | 41.00K | 39.00K | 41.00K | 40.00K | 37.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -373.00K | -938.00K | 3.00M | 4.16M | 13.94M |
| Change in Net Operating Assets | -818.00K | -3.15M | -4.89M | -2.59M | -5.26M |
| Cash from Operations | -84.02M | -77.26M | -65.73M | -47.68M | -39.21M |
| Capital Expenditure | -18.00K | -9.00K | -2.00K | -19.00K | -32.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20.52M | -194.30M | -206.80M | -195.10M | -184.97M |
| Cash from Investing | 20.51M | -194.31M | -206.80M | -195.12M | -185.01M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 569.00K | 161.35M | 161.35M | 161.35M | 161.50M |
| Repurchase of Common Stock | -11.00K | -4.00K | -1.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 0.00 | 92.06M |
| Repurchase of Preferred Stock | -- | -- | -- | -234.00K | -234.00K |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 68.14M | 64.75M | 64.75M |
| Cash from Financing | 558.00K | 161.35M | 229.49M | 225.87M | 318.07M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -62.96M | -110.22M | -43.04M | -16.93M | 93.85M |